Current strategies for predicting side effects from second generation antipsychotics in youth

Area of Science:

• Pediatric pharmacology
• Child and adolescent psychiatry
• Clinical toxicology

Background:

• Second-generation antipsychotics (SGAs) are widely used for pediatric conditions.
• While generally safer than older agents, SGAs carry risks including movement disorders, weight gain, hormonal changes, and rare severe events like neuroleptic malignant syndrome.
• Predicting which children are at higher risk for specific adverse events is essential for safe prescribing.

Purpose of the Study:

• To review clinical, pharmacological, and genetic factors that predict side effects and toxicities associated with SGAs in children.
• To provide insights for prescribers to mitigate risks and optimize treatment outcomes.

Main Methods:

• Literature review and synthesis of existing studies on SGA side effects in pediatric populations.
• Analysis of clinical observations, pharmacological data, and emerging pharmacogenetic research.
• Commentary on the evidence for predictive factors.

Main Results:

• Older children or those with poor early treatment response may face higher risks for movement disorders.
• Younger, antipsychotic-naive children are more susceptible to significant weight gain.
• Pharmacogenetic variations show potential for improving drug selection and dosing, though research is less extensive.

Conclusions:

• Clinical, pharmacological, and genetic factors can help predict SGA-associated adverse events in children.
• Integrating these factors into predictive models can support clinical decision-making and advance precision medicine for pediatric patients.
• Further research into pharmacogenetics is warranted to refine treatment strategies.